Cargando…

Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas

Identifying highly disabled patients or at high risk of psychiatric comorbidity is crucial for migraine management. The burden of migraine increases with headache frequency, but the number of headache days (HDs) per month after which disability becomes severe or the risk of anxiety and depression is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Irimia, P., Garrido-Cumbrera, M., Santos-Lasaosa, S., Aguirre-Vazquez, M., Correa-Fernández, J., Colomina, I., Pozo-Rosich, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050317/ https://www.ncbi.nlm.nih.gov/pubmed/33859216 http://dx.doi.org/10.1038/s41598-021-87352-2

Ejemplares similares

Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
por: Torres-Ferrus, Marta, et al.
Publicado: (2020)

Determination of anxiety, mood disorders and disability in cluster and migraine headache
por: Gonzalez, C, et al.
Publicado: (2013)

Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials
por: Reuter, Uwe, et al.
Publicado: (2019)

Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine
por: Lipton, Richard B., et al.
Publicado: (2020)

European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)
por: Sacco, Simona, et al.
Publicado: (2020)

Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance
por: Sacco, Simona, et al.
Publicado: (2021)

Refractory migraine in a headache clinic population
por: Irimia, Pablo, et al.
Publicado: (2011)

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
por: Bendtsen, Lars, et al.
Publicado: (2018)

Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine
por: Buse, Dawn C., et al.
Publicado: (2020)

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis
por: Matharu, Manjit, et al.
Publicado: (2017)

Low-value care practice in headache: a Spanish mixed methods research study
por: Pozo-Rosich, Patricia, et al.
Publicado: (2020)

MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
por: Belvís, Robert, et al.
Publicado: (2021)

Prevalence of Headache Days and Disability 3 Years After Participation in the Childhood and Adolescent Migraine Prevention Medication Trial
por: Powers, Scott W., et al.
Publicado: (2021)

Psychological factors associated with headache frequency, intensity, and headache-related disability in migraine patients
por: Klonowski, Theresa, et al.
Publicado: (2021)

Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study
por: Pozo-Rosich, Patricia, et al.
Publicado: (2021)

Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process
por: Steiner, Timothy J, et al.
Publicado: (2022)

Validation of the Spanish version of the migraine disability assessment questionnaire (MIDAS) in university students with migraine
por: Rodríguez-Almagro, Daniel, et al.
Publicado: (2020)

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
por: Caronna, E., et al.
Publicado: (2021)

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
por: Caronna, E., et al.
Publicado: (2021)

Improving to Four or Fewer Monthly Headache Days Per Month Provides a Clinically Meaningful Therapeutic Target for Patients with Chronic Migraine
por: Kaniecki, Robert G., et al.
Publicado: (2023)

The Neck Disability Index Reflects Allodynia and Headache Disability but Not Cervical Musculoskeletal Dysfunction in Migraine
por: Liang, Zhiqi, et al.
Publicado: (2022)

Relationships between headache frequency, disability, and disability-related unemployment among adults with migraine
por: Shapiro, Robert E, et al.
Publicado: (2023)

Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology’s Headache Study Group()
por: Morollón, N., et al.
Publicado: (2020)

Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research
por: Caronna, Edoardo, et al.
Publicado: (2021)

Real world preventative drug management of migraine among Spanish neurologists
por: García-Azorin, D., et al.
Publicado: (2019)

Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society
por: Diener, Hans Christoph, et al.
Publicado: (2021)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
por: Caronna, Edoardo, et al.
Publicado: (2021)

InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers
por: Gago-Veiga, AB, et al.
Publicado: (2021)

The impact of remission and coexisting migraine on anxiety and depression in cluster headache
por: Kim, Byung-Su, et al.
Publicado: (2020)

Quality of Sleep and Disability Associated with Headache: Migraine versus Tension-Type Headache: A Comparative Study
por: Singh, Angad Harshbir, et al.
Publicado: (2023)

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days
por: VanderPluym, Juliana, et al.
Publicado: (2018)

Reliability and Validity of the Migraine Disability Assessment Scale among Migraine and Tension Type Headache in Iranian Patients
por: Zandifar, Alireza, et al.
Publicado: (2014)

60. A Comparison of Outcomes in Trigger Site Deactivation Surgery: A Systematic Review and Meta-analysis of the Migraine Headache Index versus Monthly Migraine Days
por: Ormseth, Benjamin, et al.
Publicado: (2023)

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
por: Diener, Hans-Christoph, et al.
Publicado: (2019)

The relation of sexual function to migraine-related disability, depression and anxiety in patients with migraine
por: Eraslan, Defne, et al.
Publicado: (2014)

Prevalence, frequency, and disability of migraine headaches and tension headaches among the general population in the Eastern Region of Saudi Arabia
por: AlBarqi, Mohammed, et al.
Publicado: (2022)

The effectiveness of Orem's self-care program on headache-related disability in migraine patients
por: Mahmoudzadeh-Zarandi, Fatemeh, et al.
Publicado: (2016)

The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF)
por: Leonardi, M., et al.
Publicado: (2005)

EHMTI-0273. Onabotulinotoxin type A is a therapeutic option in chronic cluster headache
por: Mas-Sala, N, et al.
Publicado: (2014)

Effect of Migraine Headache on Productivity of Patients According to Migraine Disability Assessment Score: A Cross-Sectional Study
por: Jawed, Shafaq, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dsbq7g1a6dt65lf6cqs4sfb4il